| Optimal timing of allogeneic hematopoietic stem cell transplant in MDS |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria |
|
Expert Review of Clinical Pharmacology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score-matched study |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study |
|
Lancet Hematology |
Myelodysplastic Syndromes (MDS) |
| Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress |
|
Expert Review of Anticancer Therapies |
Myelodysplastic Syndromes (MDS) |
| Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
